Preliminary clinical study on treatment of prostate cancer with Cyber-Knife

Objective To evaluate the safety and effectiveness of ultra-hypofractionated stereotactic body radiotherapy in the treatment of prostate cancer. Methods A total of 26 patients with prostate cancer treated with Cyber-Knife from May 2010 to May 2018 were analyzed retrospectively. The median age of the patients was 69 years old (range, 57 to 87). Ultra-hypofractionated radiotherapy was delivered in five fractions of 7.0-7.5 Gy for a total dose of 35.0-37.5 Gy. Androgen deprivation therapy (ADT) was administered in combination with the Cyber-Knife. The primary endpoints were radiation toxicity, PSA-response, local control and symptom alleviation, while the secondary endpoints were progression-free survival and overall survival. Results No graded ≥3 acute and late radiation toxicities occurred during follow-up. The acute toxicity of Grades 1 and 2 was 38.4% and 19.2%, while the late toxicity of Grades 1 and 2 was 30.8% and 3.8%, respectively. At a median follow-up of 22.44 months, for patients with localized stage, PSA level was decreased significantly after radiotherapy (Z=2.900, 2.794, 2.510, 2.090, P 0.05). Conclusions Ultra-hypofractionated stereotactic body radiotherapy is a safe and effective treatment for patients with prostate cancer. Key words: Ultra-hypofractionated; Stereotactic body radiotherapy; Cyber-Knife; Prostate cancer; Prostate-specific antigen